prohibited list comes up often in conversation and rarely with the context attached. Here we lay out the basics in order, then work through the practical considerations.
Updated 2026-05-18. Numbers and descriptions here follow the published literature rather than marketing material.
Laboratory work on thymosin beta-4 describes binding to monomeric actin and effects on cell migration, angiogenesis, and inflammatory signaling in cultured cells. Animal models have examined skin, corneal, and cardiac repair after injury, with outcomes reported mainly in preclinical literature. Most of that evidence concerns the parent protein rather than preparations labelled TB-500, so extrapolation from animal findings to a specific commercial product remains uncertain. Whether the two behave identically in living systems has not been established in controlled human studies.
No major regulatory agency has approved TB-500 for therapeutic use, and it holds no pharmacopoeial monograph. The name appears on the World Anti-Doping Agency prohibited list within the class covering peptide hormones, growth factors, and related substances. Detection in doping control relies on mass spectrometric methods applied to urine, often after preparation steps that concentrate the analyte. Discussion of TB-500 therefore clusters in biochemistry, sports medicine, and anti-doping literature rather than in registered clinical trials.
Research peptides are typically supplied as a white to off-white lyophilised powder in a sealed vial. The dry solid is more stable than a solution and is normally kept refrigerated or frozen until use. Dissolution is usually done in water, phosphate-buffered saline or a similar aqueous medium, depending on the assay. Because the material is hygroscopic and easily contaminated, opening vials in a low-humidity environment and recording the lot number before use are standard laboratory practices.
Once in solution, short peptides are generally less stable than the dry powder, and repeated freeze-thaw cycles are a common cause of loss. Laboratory guidance usually calls for aliquoting on first dissolution and storing aliquots at -20 °C or below, away from light. Adsorption to plastic and glass surfaces can lower measured concentration, particularly at low concentrations, so container material and buffer choice can affect results. Visible cloudiness, colour change or unexpected precipitate is a signal to re-check the material.
Purity is normally assessed by reversed-phase HPLC, with the main peak reported as a percentage of total peak area, while identity is confirmed by mass spectrometry. Electrospray and MALDI-TOF instruments are both used, and the observed mass is compared with the value calculated from the stated sequence. Ion-exchange or size-exclusion methods appear where aggregation or charge variants are of interest. Water content, counter-ion content and residual trifluoroacetate from purification are separate variables that can shift the measured mass and should be weighed when reading a certificate of analysis.
| Property | Value | Notes |
|---|---|---|
| Molecular mass | Approximately 4963 Da for full-length thymosin beta-4 | Value applies to the parent protein; fragment products may differ |
| Appearance | White to off-white lyophilized powder | Typical form of supplied synthetic peptide |
| Solubility | Freely soluble in water | Polar peptide; dissolves readily in aqueous buffer |
| Storage of dry powder | −20 °C, desiccated, protected from light | Standard laboratory practice for peptides |
| Typical detection method | Liquid chromatography–tandem mass spectrometry | Used in purity testing and anti-doping analysis |
Dry powder is commonly held at minus twenty degrees Celsius, with some suppliers recommending lower temperatures for long-term archival storage. Once dissolved, solutions are typically kept cold and protected from light, since aqueous peptide solutions can lose integrity through hydrolysis or oxidation over time. Stability data specific to this fragment are limited in the public literature, and much of the guidance comes from general peptide handling practice rather than from controlled degradation studies. Users therefore treat stated shelf lives as approximate rather than fixed.
Identity and purity are normally assessed with reversed-phase high-performance liquid chromatography, paired with mass spectrometry to confirm molecular mass. A certificate of analysis reports a purity percentage, usually derived from chromatographic peak area, but that figure does not by itself prove a correct sequence or the absence of counterions. Independent verification may include amino acid analysis or peptide mapping. Batch-to-batch variation is a documented concern in the research chemical market, and the gap between a quoted purity value and actual peptide content can be substantial when the material is a salt or retains residual water.
Lyophilized peptide arrives as a dry cake that should stay sealed until use. Reconstitution is generally performed with sterile water or a buffered solution, and the resulting liquid should be handled gently to limit mechanical stress. Repeated freeze-thaw cycles are widely described as harmful to short peptides, so dividing a reconstituted batch into single-use portions is a common practice. Laboratories also record the solvent, concentration, and date of preparation on the vial label to keep later measurements traceable.
Material is normally supplied as a lyophilised powder in a sealed vial. The powder is hygroscopic, so exposure to humid air leads to water uptake, caking and gradual loss of the fluffy texture that indicates a good freeze-dry. Vials are best kept sealed with desiccant, protected from light and stored cold. Letting a cold vial warm to room temperature before opening reduces condensation on the contents. Purity is normally reported from a chromatographic run, and that figure applies to the batch as tested rather than to the vial after repeated opening.
Once dissolved, the peptide is far less stable than the dry powder. Aqueous solutions are subject to hydrolysis, oxidation at susceptible residues and gradual loss of material through adsorption onto glass and plastic surfaces. Terminal glutamine can cyclise under some conditions, producing a related species that complicates purity assessment. Dilute solutions tend to lose a larger fraction of material to surfaces than concentrated ones. Buffers, pH and ionic strength all influence the rate of change, so stability figures are only meaningful when those parameters are stated alongside the storage interval.
Detection in biological samples relies on mass spectrometry, typically liquid chromatography coupled to tandem mass spectrometry after peptide extraction and enrichment. Intact peptides can also be confirmed by high-resolution mass measurement together with fragmentation data. Detection windows in urine are short because the peptide is degraded by proteases and cleared quickly, and concentrations are low. Many jurisdictions treat the compound as a prohibited substance in sport, grouped with peptide hormones and related factors, while it is not an approved therapeutic product. Identity and purity statements therefore rest on certificates of analysis, ideally issued by an independent laboratory.
Paper-based microfluidic devices are proposed to provide portable, cheap, and user-friendly medical diagnostic systems. Paper based microfluidics rely on the phenomenon of capillary penetration in porous media. To tune fluid penetration in porous substrates such as paper in two and three dimensions, the pore structure, wettability and geometry of the microfluidic devices can be controlled while the viscosity and evaporation rate of the liquid play a further significant role. Many such devices feature hydrophobic barriers on hydrophilic paper that passively transport aqueous solutions to outlets where biological reactions take place. Paper-based microfluidics are considered as portable point-of-care biosensors used in a remote setting where advanced medical diagnostic tools are not accessible. Current applications include portable glucose detection and environmental testing, with hopes of reaching areas that lack advanced medical diagnostic tools.
=== Zhejiang === In October 2002, Xi left Fujian and became the deputy governor, acting governor and deputy Party secretary of neighbouring Zhejiang. He eventually took over as provincial Party Committee secretary after the 16th Party National Congress, occupying a top provincial office for the first time in his career. In November 2002, he was elected a full member of the 16th Central Committee by the 16th Party National Congress, marking his ascension to the national stage. While in Zhejiang, Xi presided over reported growth rates averaging 14% per year. During this period, Zhejiang increasingly transitioned away from heavy industry. Xi's career in Zhejiang was marked by a tough and straightforward stance against corrupt officials. This earned him a name in the national media and drew the attention of China's top leaders. Between 2004 and 2007, Li Qiang acted as Xi's chief of staff through his position as secretary-general of the Zhejiang Party Committee, where they developed close mutual ties. During this period, Xi and Li drafted the Double Eight Strategy, which listed eight comparative advantages of Zhejiang and eight corresponding actions to improve the province.
=== From a reservoir === Creating a new droplet from a reservoir of liquid can be done in a similar fashion to splitting a droplet. In this case, the reservoir remains stationary while a sequence of electrodes are used to draw liquid out of the reservoir. This drawn liquid and the reservoir form a neck of liquid, akin to the neck of a splitting droplet but longer, and the collapsing of this neck forms a dispensed droplet from the drawn liquid. In contrast to splitting, though, dispensing droplets in this manner is inconsistent in scale and results. There is no reliable distance liquid will need to be pulled from the reservoir for the neck to collapse, if it even collapses at all. Because this distance varies, the volumes of dispensed droplets will also vary within the same device. Due to these inconsistencies, alternative techniques for dispensing droplets have been used and proposed, including drawing liquid out of reservoirs in geometries that force a thinner neck, using a continuous and replenishable electrowetting channel, and moving reservoirs into corners so as to cut the reservoir down the middle. Multiple iterations of the latter can produce droplets of more manageable sizes.
Sources: en.wikipedia.org
Ernst on developing the first two-dimensional NMR experiments, and established the nuclear Overhauser effect as a convenient way of measuring distances within proteins. This research later led to the complete assignment of resonances for among others the bovine pancreatic trypsin inhibitor and glucagon. In October 2010, Wüthrich participated in the USA Science and Engineering Festival's Lunch with a Laureate program where middle and high school students will get to engage in an informal conversation with a Nobel Prize–winning scientist over a brown-bag lunch. Wüthrich is also a member on the USA Science and Engineering Festival's Advisory Board and a supporter of the Campaign for the Establishment of a United Nations Parliamentary Assembly, an organisation which campaigns for democratic reform in the United Nations. Wüthrich is a member of the Executive Advisory Board of the World.Minds Foundation, where he contributes to international dialogue on science, research, and innovation policy.
== Cited literature == Bilstein, Roger E. (1996). Stages to Saturn: A Technological History of the Apollo/Saturn Launch Vehicles. Washington: Scientific and Technical Information Branch, National Aeronautics and Space Administration. ISBN 0-16-048909-1. Burgess, Colin; Hall, Rex (2009). The First Soviet Cosmonaut Team. Chichester, UK: Praxis Publishing. ISBN 978-0-387-84824-2. LCCN 2008935694. Burgess, Colin; Kate Doolan; Bert Vis (2003). Fallen Astronauts: Heroes Who Died Reaching for the Moon. Lincoln: University of Nebraska Press. ISBN 0-8032-6212-4. Brzezinski, Matthew (2007). Red Moon Rising: Sputnik and the Hidden Rivalries that Ingnited the Space Race. New York: Times Books, Henry Holt and Company. ISBN 978-0-8050-8147-3. Burrows, William E. (1998). This New Ocean: The Story of the First Space Age. New York: Random House. ISBN 978-0-679-44521-0. Cadbury, Deborah (2006). Space Race: The Epic Battle Between America and the Soviet Union for Dominance of Space. New York: Harper Collins Publishers. ISBN 978-0-06-084553-7. Chaikin, Andrew (1994). A Man on the Moon: The Triumphant Story of the Apollo Space Program. New York: Penguin Books. ISBN 0-14-027201-1. Chertok, Boris (2005). Rockets and People Volumes 1-4. National Aeronautics and Space Administration. Retrieved May 29, 2022. Cornwell, John (2003). Hitler's Scientists: Science, War, and the Devil's Pact. New York: Viking Press. ISBN 0-670-03075-9. Dallek, Robert (2003). An Unfinished Life: John F. Kennedy, 1917–1963. Boston: Little, Brown and Company. ISBN 0-316-17238-3. Leonard, David (2019). Moon Rush.
Hormonal IUDs were developed in the 1970s following the development of the copper IUD in the 1960s and 1970s. Dr. Antonio Scommenga, working at the Michael Reese Hospital in Chicago, discovered that administering progesterone inside the uterus could have contraceptive benefits. With knowledge of Scommegna's work, a Finnish doctor, Jouni Valter Tapani Luukkainen, created the T-shaped IUD that released progesterone, marketed as the Progestasert System in 1976. This IUD had a short, 1-year lifespan and never achieved widespread popularity. Following this relative lack of success, Dr. Luukkainen replaced the progesterone with the hormone levonorgestrel to be released over a five-year period, creating what is now Mirena. The Mirena IUD was studied for safety and efficacy in two clinical trials in Finland and Sweden involving 1,169 women who were all between 18 and 35 years of age at the beginning of the trials. The trials included predominantly Caucasian women who had been previously pregnant with no history of ectopic pregnancy or pelvic inflammatory disease within the previous year. Over 70% of the participants had previously used IUDs. In 2013 Skyla, a lower dose levonorgestrel IUD effective for up to three years, was approved by the FDA. Skyla has a different bleeding pattern than Mirena, with only 6% of women in clinical trials becoming amenorrheic (compared to approximately 20% with Mirena). The city of Turku, Finland, is currently the only production site for the Mirena contraceptive family.
The Kentucky Futurity is a stakes race for three-year-old trotters, held annually at The Red Mile in Lexington, Kentucky since 1893. It is part of the Triple Crown of Harness Racing for Trotters. In the 2007 race, Donato Hanover's winning time of 1:51.1 set the world record for a 1-mile trotting horse. In winning the 2016 running of the Kentucky Futurity, Marion Marauder became the ninth horse from 124 runnings to win the Triple Crown of Harness Racing for Trotters. 2025 г. | Emoticon Legacy | L.Roy | 1.49,2 | Победитель приза Кентукки Футурити .
Sources: en.wikipedia.org
== External links == Media related to Phyllostachys nigra at Wikimedia Commons Data related to Phyllostachys nigra at Wikispecies "Phyllostachys nigra". Integrated Taxonomic Information System. John Lindley (1835). "Description of Bambusa nigra". The Penny Cyclopædia of the Society for the Diffusion of Useful Knowledge. Vol. 3. p. 357.
desynapsis The failure of homologous chromosomes that have synapsed normally during pachynema to remain paired during diplonema. Desynapsis is usually caused by the improper formation of chiasmata. Contrast asynapsis.
=== Academic career === From 1943 to 1955, Fox was a full professor at Iowa State College. Fox became the head of the Iowa Agricultural Experimental Station's Chemistry Department from 1949 to 1955. In 1955, Sidney W. Fox moved to Florida State University and held the position of Professor of Chemistry, Director of the Oceanographic Institute, and Director of the Institute for Space Biosciences. In 1964, Fox moved to the University of Miami where he was a professor and the director of the Institute for Molecular Evolution for 25 years. The program was supported by the National Aeronautics and Space Administration (NASA). Fox also taught at the Southern Illinois University in the Department of Plant Biology as a Distinguished Research Professor. From there, Fox moved to the University of South Alabama where he was entitled Distinguished Research Scientist in the Marine Sciences department in 1993.
Sources: en.wikipedia.org
Not necessarily. TB-500 is a commercial label that suppliers apply to synthetic peptides described as thymosin beta-4 or a fragment of it. Published research most often studies the full-length protein, so statements about one do not automatically transfer to the other.
No. No major regulatory authority lists an approved product under this name, and no pharmacopoeial monograph exists for it. Material sold under the label is therefore supplied outside approved pharmaceutical channels, which affects the quality documentation available.
It falls within a prohibited class covering peptide hormones and growth factors, based on presumed effects on tissue repair and blood vessel formation. Anti-doping laboratories have published mass spectrometry methods for detecting thymosin beta-4 related peptides in urine samples.
Sealed, desiccated and protected from light, at -20 °C or lower for long-term storage. Short-term storage at refrigerator temperature is common in working laboratories.